Lipid-lowering agents and new onset diabetes mellitus (Q43058605)

13 November 2017

0 references

Lipid-lowering agents and new onset diabetes mellitus (English)

1 reference

13 November 2017

1

1 reference

13 November 2017

Dimitri P Mikhailidis

series ordinal

4

object named as

Dimitri P Mikhailidis

1 reference

13 November 2017

Konstantinos Tziomalos

series ordinal

2

1 reference

13 November 2017

Asterios Karagiannis

series ordinal

3

1 reference

13 November 2017

language of work or name

English

0 references

publication date

1 August 2010

1 reference

Expert Opinion on Pharmacotherapy

13 November 2017

1 reference

13 November 2017

11

1 reference

13 November 2017

1965-1970

1 reference

13 November 2017

12

1 reference

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

13 November 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

Reduced incidence of new-onset diabetes mellitus after renal transplantation with 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors (statins).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

Statin therapy and risk of developing type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

Rosuvastatin in older patients with systolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

Adverse prognostic significance of new diabetes in treated hypertensive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

The relative importance of modifiable potential risk factors of type 2 diabetes: a meta-analysis of two cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

Role of vitamin D in the pathogenesis of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

Ethnic differences in mortality, end-stage complications, and quality of care among diabetic patients: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

Impact of the population at risk of diabetes on projections of diabetes burden in the United States: an epidemic on the way.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

Vascular risk factors in South Asians

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

Epidemic obesity and type 2 diabetes in Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

Effects of niacin on glucose control in patients with dyslipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

Niacin in cardiovascular prevention: mechanisms, efficacy, and safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

The effect of body mass index on fasting blood glucose and development of diabetes mellitus after initiation of extended-release niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

Evaluation of efficacy and safety of fixed dose lovastatin and niacin(ER) combination in asian Indian dyslipidemic patients: a multicentric study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489553

10.1517/14656566.2010.489553

21 January 2018

Identifiers

DOI

1 reference

13 November 2017

1 reference